Study summary · research use only
Shared mechanistic pathways of glucagon signalling: Unlocking its potential for treating obesity, metabolic dysfunction-associated steatotic liver disease, and other cardio-kidney-metabolic conditions
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This review discusses glucagon signaling and its receptor (GCGR), expressed mainly in liver and kidney, in relation to obesity, metabolic dysfunction-associated steatotic liver disease (MASLD), and other cardio-kidney-metabolic conditions, citing both animal and human studies. It notes that GCGR antagonists increased body weight, hepatic fat, and serum lipids in people with type 2 diabetes in clinical trials, and that GCGR-based multi-agonists including mazdutide, survodutide, and retatrutide have shown substantial weight loss in early clinical trials in people with obesity, with liver health improvements in those with MASLD. The authors state the physiological pathways of chronic GCGR activation in humans remain to be defined, and highlight interest in ongoing phase 3 trials.
Abstract
Glucagon is a pancreatic peptide hormone whose receptor (GCGR) is expressed in the liver, kidney, and, to a lesser extent, various other tissues. Glucagon is well known as the counterpart to insulin in glucose homeostasis. However, recent evidence has revealed other potential roles of glucagon, which include the regulation of amino acid metabolism via a liver-pancreatic alpha cell axis, stimulation of lipolysis and mitochondrial fat oxidation in the liver (and possibly in other tissues), reduction of caloric intake, and an increase in energy expenditure (at least in animal models). These advances in basic science-together with clinical trials that found GCGR antagonists increased body weight, hepatic fat, and serum lipids in people with type 2 diabetes-are driving the development of GCGR-based agonists for the treatment of obesity, metabolic dysfunction-associated steatotic liver disease (MASLD), and other cardio-kidney-metabolic diseases. Due to the hyperglycaemic effects of glucagon, these unimolecular compounds also incorporate moieties that activate the glucagon-like peptide-1 (GLP-1) receptor, which stimulates insulin secretion to lower blood glucose levels. In early clinical trials, several GCGR-based multi-agonists (mazdutide, survodutide [being developed by the sponsor of this review], retatrutide) demonstrated substantial efficacy for eliciting weight loss in people with obesity while improving liver health in those with MASLD. However, the physiological and molecular pathways modulated by chronic pharmacological activation of the GCGR in humans remain to be delineated, as do its potential risks. Thus, there is great interest in the ongoing phase 3 clinical trials of these compounds. As data for their safety and efficacy emerge, glucagon's role in energy regulation and lipid metabolism will become clearer, along with warranting a potential new therapeutic option for obesity and MASLD.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.